Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5075 - Diagnostic and Prognostic Impact of Plasma Osteopontin in Nasopharyngeal Carcinoma


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Head and Neck Cancers


Jin-Ching Lin


Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374


J. Lin1, W. Wang2, Y.C. Liu1

Author affiliations

  • 1 Radiotion_oncology, Taichung Veterans General Hospital, 40705 - Taichung/TW
  • 2 Department Of Nursing, Hung Kuang University, 40705 - Taichung/TW


Abstract 5075


We investigated the diagnostic and prognostic impact of plasma osteopontin (pOPN) concentrations in advanced nasopharyngeal carcinoma (NPC).


Pre-treatment plasma samples from 138 patients with previously untreated and biopsy-proven NPC were collected. Plasma samples from another 70 healthy volunteer were served as control. OPN concentrations were measured by the enzyme-linked immunosorbent assay (ELISA). The patient characteristics were- age range 24-83 and median 48 years, male/female=97/41, WHO pathology type I/II/III=1/105/32, stage III/IV(M0)/IVC(M1) = 57/73/8. The treatment consisted of radiotherapy alone (2), concurrent chemoradiotherapy (28), and neoadjuvant chemotherapy plus radiotherapy (100) for M0 patients, and systemic chemotherapy with or without radiotherapy for M1 patients (8).


NPC patients (median 97.2 ng/mL; interquartile range 72.1-130.4) had significantly higher pOPN level than normal control (median 61.6 copies/ml; interquartile range 44.9-88.1), P100 ng/mL) correlated with some clinically poor prognostic factors, such as older age, male gender, advanced T-stage, and advanced overall stage. Pretreatment pOPN affected patients’ survival as well as rates of distant failure. The 5-year overall survival (56.6% vs. 81.4%, P=0.0036) and metastasis-free survival (66.3% vs. 81.2%, P=0.0726) were significantly lower in patients with pretreatment pOPN > 100 ng/mL than in those with pOPN < 100 ng/mL.


Pretreatment pOPN levels can serve as a useful diagnostic and prognostic marker for advanced NPC.

Clinical trial identification

Legal entity responsible for the study

Taichung Veteran General Hospital


Taichung Veteran General Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.